Permanent facial hypopigmentation following treatment with imiquimod cream [12]

Clinical and Experimental Dermatology

Volumn 31, Issue 5, 2006, Pages 721-722

  Mendonca C O ^a   Yates, V M ^a  

^a HOPE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTOKINE; IMIQUIMOD;

AGED; CASE REPORT; CREAM; DRUG DOSAGE FORM; DRUG SAFETY; HISTOLOGY; HUMAN; HYPERPIGMENTATION; HYPOPIGMENTATION; IMMUNE SYSTEM; LETTER; MALE; PRIORITY JOURNAL;

AGED; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; FACIAL NEOPLASMS; HUMANS; HYPOPIGMENTATION; MALE; STEROIDS; TREATMENT OUTCOME;

EID: 33746113755     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2006.02175.x     Document Type: Letter

References (5)

1. Hemmi Kaisho T, Takeuchi O et al. Small antiviral compounds activate immune cells via the TLR7 My D88-dependent signalling pathway. Nat Immunol 2002; 3: 196-200.
2. Gibson S, Lind J, Riter T et al. Plasmacytoid dendritic cells produce cytokines and mature in respose to the TLR7 agonists, imiquimod and resiquimod. Cellular Immunol 2002; 218: 74-86.
3. Miller RL, Gerster JF, Owens ML et al. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol 1992; 21: 1-14.
4. Gollnick H, Guillen Barona C, Frank RGP et al. Efficacy by clinical evaluation of imiquimod 5% cream in the treatment of superficial basal cell carcinoma: initial results from an ongoing, long-term follow-up study in Europe. J Am Acad Dermatol 2004; 50: 124. [Abstract]
5. Geisse J, Caro I, Lindholm J et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomised vehicle- controlled studies. J Am Acad 2004; 50: 722-33.